Q2 2025 Performance - Total revenue decreased by 5% year-over-year, from $63.7 million to $60.8 million[16] - Adjusted Gross Profit decreased by 6% year-over-year, from $53.1 million to $50.0 million, with Adjusted Gross Profit margin contracting by 110 bps to 82%[16] - Adjusted EBITDA decreased by 11% year-over-year, from $20.9 million to $18.7 million, with Adjusted EBITDA margin contracting by 210 bps to 31%[16,18] - Unlevered Free Cash Flow (uFCF) decreased by 47% year-over-year, from $21.5 million to $11.5 million[20] Revenue Mix - Subscription revenue mix was 96%, with a 6% year-over-year decline[17] - Professional Services revenue mix was 4%, with a 46% year-over-year growth[17] Cash Flow and Balance Sheet - Cash, cash equivalents & short-term investments decreased by 38% year-over-year, from $296.5 million to $184.2 million[20] - Total debt outstanding decreased by 32% year-over-year, from $250.9 million to $170.6 million[20] - Total remaining performance obligations increased by 1% year-over-year, from $257.6 million to $261.4 million[20] Guidance - Q3 2025 Revenue is expected to be between $59.0 million and $60.0 million, a decrease of 6%-4% year-over-year[24] - Full Year 2025 Revenue is expected to be between $237.0 million and $240.0 million, a decrease of 6%-5% year-over-year[24]

Core Viewpoint - Definitive Healthcare Corp. will report its financial results for the second quarter of 2025 on August 7, 2025, after market close, and will host a conference call to discuss these results [1]. Group 1 - The financial results will cover the period ended June 30, 2025 [1]. - A conference call and webcast will take place at 5:00 PM (ET) / 2:00 PM (PT) on the same day [1]. - The event will be accessible via a live audio webcast on the company's Investor Relations website [2]. Group 2 - A live dial-in option will be available for participants, with domestic and international numbers provided [2]. - A replay of the conference call will be available until September 6, 2025, with specific access numbers and a passcode [2]. Group 3 - Definitive Healthcare aims to transform data, analytics, and expertise into healthcare commercial intelligence, helping clients identify markets and opportunities [3]. - The company offers SaaS products and solutions designed to facilitate commercial success in the healthcare market [3].

Q1 2025 Performance - Total revenue decreased by 7% year-over-year to $59.2 million[16] - Adjusted EBITDA declined by 27% year-over-year, reaching $14.7 million[18] - Adjusted EBITDA margin contracted by 670 basis points year-over-year to 25%[18] - Unlevered Free Cash Flow (uFCF) was $22.9 million, a 19% decrease year-over-year[21] - Cash, cash equivalents, and short-term investments totaled $200.7 million, a 32% decrease year-over-year[21] Revenue Mix - Subscription revenue, constituting 97% of the total, experienced a 7% year-over-year decline[17] - Professional Services revenue, accounting for 3% of the total, grew by 9% year-over-year[17] Q2 and FY 2025 Guidance - The company projects Q2 2025 revenue to be between $58.5 million and $60.0 million, representing a year-over-year decrease of 8% to 6%[25] - The company anticipates full-year 2025 revenue to be between $234.0 million and $240.0 million, a year-over-year decrease of 7% to 5%[25] - The company expects full-year 2025 Adjusted EBITDA to be between $61.0 million and $65.0 million, representing 26% to 28% of revenue[25] Shareholder Statistics - Sponsor ownership (as-if converted) is 77,778,491 shares, representing 52.3% of total ownership[30] - Management, Directors & employees ownership is 25,424,644 shares, representing 17.1% of total ownership[30] - Float is 45,438,239 shares, representing 30.6% of total ownership[30]

Core Insights - Definitive Healthcare Corp. reported first quarter results exceeding guidance for both revenue and earnings, driven by strong new customer acquisition and operational efficiency [3][4][6] - The company anticipates revenue for the second quarter of 2025 to be between $58.5 million and $60.0 million, with adjusted operating income expected to be between $12.0 million and $13.0 million [7][8] - For the full year 2025, revenue is projected to be in the range of $234.0 million to $240.0 million, with adjusted net income expected to be between $30.0 million and $34.0 million [13] Financial Performance - Revenue for Q1 2025 was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024 [6] - The net loss for the quarter was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024 [6] - Adjusted net income was $7.0 million, down from $13.0 million in Q1 2024, while adjusted EBITDA was $14.7 million, or 25% of revenue, compared to $20.0 million, or 32% of revenue in Q1 2024 [6][31] Customer Acquisition and Business Development - The company secured several new customer wins in Q1 2025, including a California-based medical device company and a regional health system in the Southern US, highlighting the effectiveness of its data and insights [7] - Definitive Healthcare is expanding its focus on digital marketing activation partnerships, having signed two leading healthcare advertising agencies [7] Cash Flow and Operational Efficiency - Cash flow from operations was $26.1 million in the quarter, with unlevered free cash flow at $22.9 million [6] - The company continues to focus on operational efficiency despite rising macroeconomic uncertainty, maintaining a positive outlook for meeting full-year financial targets [3][4]

Financial Results Announcement - Definitive Healthcare Corp. will report its financial results for the first quarter ended March 31, 2025, on May 8, 2025, after market close [1] - A conference call and webcast will be held at 5:00 PM (ET) / 2:00 PM (PT) to discuss the financial results [1] Webcast and Replay Information - A live audio webcast of the event will be available on Definitive Healthcare's Investor Relations website [2] - A replay of the conference call will be available through June 7, 2025, with specific dial-in numbers and a passcode provided for access [2] Company Overview - Definitive Healthcare aims to transform data, analytics, and expertise into healthcare commercial intelligence, helping clients identify markets and opportunities [3] - The company's SaaS products and solutions are designed to create new paths to commercial success in the healthcare market [3]

Group 1 - Definitive Healthcare announced the hiring of two senior leaders, Kate Hastings as Chief Customer Officer and Benjamin Graboske as EVP, Technology, Engineering and Chief Data Officer [1] - The Human Capital Management and Compensation Committee granted inducement awards consisting of 172,414 time-based restricted stock units (RSUs) to Hastings and 1,018,330 time-based RSUs to Graboske, effective March 3, 2025 [1] - The awards were individually negotiated and granted as an inducement material to the commencement of employment in accordance with Nasdaq Listing Rule 5635(c)(4) [1] Group 2 - Hastings' RSUs will vest 25% on February 1, 2026, with the remainder vesting in quarterly installments of 6.25% over the following three years [2] - Graboske's RSUs will vest 25% on April 1, 2026, with the remainder vesting in quarterly installments of 6.25% over the following three years [3] Group 3 - Definitive Healthcare focuses on transforming data, analytics, and expertise into healthcare commercial intelligence, helping clients identify markets, opportunities, and key personnel [4]